Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
Status:
Completed
Trial end date:
2021-08-05
Target enrollment:
Participant gender:
Summary
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex
for production of human IL-12. IL-12 is a protein that can improve the body's natural
response to disease by enhancing the ability of the immune system to kill tumor cells and may
interfere with blood flow to the tumor.
Cemiplimab-rwlc (Libtayo) is an antibody (a kind of human protein) that is being tested to
see if it will allow the body's immune system to work against glioblastoma tumors. Libtayo
(cemiplimab-rwlc) is currently FDA approved in the United States for metastatic cutaneous
cell carcinoma (CSCC), but is not approved in glioblastoma. Cemiplimab-rwlc may help your
immune system detect and attack cancer cells. Ad-RTS-hIL-12 and veledimex will be given in
combination with cemiplimab-rwlc to enhance the IL-12 mediated effect observed to date.
The main purpose of this study is to evaluate the safety and efficacy of a single tumoral
injection of Ad-RTS-hIL-12 given with oral veledimex in combination with cemiplimab-rwlc.